Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure... see more

Recent & Breaking News (TSX:PRN)

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

GlobeNewswire 13 days ago

Profound Medical Announces Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

GlobeNewswire November 4, 2024

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 - Conference Call to Follow

GlobeNewswire October 17, 2024

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

GlobeNewswire October 16, 2024

Profound Medical's PRO-Talk Live! Event Features the Present and Future of TULSA

GlobeNewswire September 16, 2024

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

GlobeNewswire September 4, 2024

Profound Medical Announces Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 - Conference Call to Follow

GlobeNewswire July 18, 2024

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

GlobeNewswire July 11, 2024

PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS

Canada NewsWire May 15, 2024

Profound Medical Receives U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

GlobeNewswire May 14, 2024

Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance

GlobeNewswire May 9, 2024

Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

GlobeNewswire May 6, 2024

Profound Medical to Release First Quarter 2024 Financial Results on May 9 - Conference Call to Follow

GlobeNewswire April 22, 2024

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 9, 2024

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 7, 2024

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

GlobeNewswire March 4, 2024

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

GlobeNewswire February 27, 2024

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 - Conference Call to Follow

GlobeNewswire February 15, 2024